List view / Grid view
22 December 2016 | By Niamh Louise Marriott, Digital Editor
TiGenix, has exercised the option granted by Takeda under the licensing agreement to make a €10 million equity investment in TiGenix...
18 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Cx601 is a suspension of allogeneic adipose-derived stem cells for the treatment of complex perianal fistulas in patients with Crohn's disease that have...
2 August 2016 | By Takeda Pharmaceutical Company Limited / TiGenix NV
Takeda and TiGenix announce that the results of the Phase 3 ADMIRE-CD trial investigating Cx601 have been published. Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn's disease...
5 July 2016 | By Victoria White, Digital Content Producer
Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally for the treatment of complex perianal fistulas in Crohn’s disease...
23 February 2015 | By TiGenix NV
TiGenix NV has announced that Dr Julian Panés endorsed the design of the Company's Phase III trial of Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease during his presentation last week at the 10th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)...
Lonza, a global leader in biological and cell therapy manufacturing and TiGenix, an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from allogeneic expanded adipose-derived stem cells (eASCs) in inflammatory and autoimmune diseases, announced today an agreement for the supply of TiGenix's eASC product, Cx601.
12 November 2014 | By TiGenix NV
TiGenix NV announced that it has completed the patient recruitment for its Phase III trial of Cx601 in Europe for the treatment of complex perianal fistulas in Crohn's patients...
